By considering stability as part of the cell line selection and cell banking paradigm, we can ensure that instability problems are not observed during clinical or commercial manufacturing.
Mark Leonard
Advertisement
Mark Leonard is the director in the cell and molecular sciences group in the department of Drug Substance Development at Wyeth Biopharma
Articles by Mark Leonard
Advertisement
Latest Updated Articles
Managing Cell Line Instability and Its Impact During Cell Line DevelopmentPublished: June 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
